Leena Menghaney

Strengthening quality assurance at the time of approval of medicines at the State level and endorsing a pro-public health patent system will be crucial to sustain India’s ability to supply quality, affordable medicines worldwide

India has the second-highest number of children with Type 1 diabetes globally. Almost a million Indians living with T1D face stigma and discrimination rooted in myths and stereotypes. With the health ministry and NCD programme failing to ensure equitable access to treatment and monitoring tools, could learnings from HIV/AIDs response help evolve legal norms against discrimination and misinformation on Type 1 diabetes?